Autres langues Galectin Therapeutics Inc.

Actions

GALT

US3632252025

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 09/09/2026			Varia. 5j.	Varia. 1 janv.
4,050 ^USD	-2,17%		-9,60%	-2,64%

14/08	Galectin Therapeutics Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
23/06	Galectin Therapeutics parvient à un accord avec la FDA sur le critère d’évaluation principal et la voie réglementaire à suivre pour belapectin chez des patients atteints de cirrhose liée à la MASH et d’hypertension portale	CI

Autres langues

14/08	Galectin Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
14/08	Galectin Therapeutics : Reports June 30, 2026 Financial Results and Provides Business Update
14/08	Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
04/08	Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet
29/06	Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell Small Cap Comp Growth Benchmark
29/06	Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell 2500 Growth Benchmark
29/06	Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell 2000 Index
29/06	Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell 2000 Value Benchmark
29/06	Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell 2000 Growth Benchmark
29/06	Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell 3000E Index
29/06	Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell 3000E Growth Benchmark
29/06	Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell 3000E Value Benchmark
29/06	Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell 2000 Dynamic Index
29/06	Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell 3000 Value Benchmark
29/06	Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell Small Cap Completeness Index
29/06	Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell 3000 Growth Benchmark
29/06	Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell 2500 Index
29/06	Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell Small Cap Comp Value Benchmark
29/06	Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell 2500 Value Benchmark
29/06	Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell 3000 Index
23/06	Galectin Therapeutics Shares Surge on Positive FDA Meeting, Phase 3 Trial Plans
23/06	Galectin Therapeutics Reaches Agreement with Fda on Primary Endpoint and Regulatory Path Forward for Belapectin in Patients with Mash Cirrhosis and Portal Hypertension
23/06	Galectin Therapeutics Says FDA Alignment Reached on Phase 3 Belapectin Trial
23/06	Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension
27/05	Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis